María Alejandra Umbacia, Agnès Calsina-Berna, Angie Nathalia Hernández-Rico, Fernan Alejandro Mendoza-Montenegro, Juan Sebastián Gallo-Hincapié, Lina Marcela Ruiz Cadena, María Fernanda Martínez-Díaz, Sebastian Del Castillo Visbal, Juan Esteban Correa-Morales
{"title":"口服氯胺酮作为一种镇痛疗法:随机临床试验的系统评价。","authors":"María Alejandra Umbacia, Agnès Calsina-Berna, Angie Nathalia Hernández-Rico, Fernan Alejandro Mendoza-Montenegro, Juan Sebastián Gallo-Hincapié, Lina Marcela Ruiz Cadena, María Fernanda Martínez-Díaz, Sebastian Del Castillo Visbal, Juan Esteban Correa-Morales","doi":"10.1080/15360288.2025.2496520","DOIUrl":null,"url":null,"abstract":"<p><p>Ketamine is an analgesic used to manage neuropathic pain, but its use is limited by side effects and intravenous administration. Recently, the use of oral and nasal administration has expanded. However, no systematic review of randomized studies on its efficacy and safety. A search was conducted in PubMed, CINHAL, and Web of Science up to December 19, 2023. Randomized studies evaluating oral ketamine for managing any type of pain were included. Articles were assessed for quality using the ROB2 tool, and results were reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The search yielded 1439 results. Six randomized studies were selected. The oral ketamine dose ranged from 0.5 to 10 mg/kg, up to a maximum of 400 mg/day. Three studies comparing oral ketamine with other analgesics found no differences between groups. Two studies compared oral ketamine to placebo; one showed a reduction in local anesthetic use and intraoperative pain, while the other found no difference. Adverse reactions were common, but their severity was not reported. Preliminary evidence suggests that oral ketamine may be considered in select patients with refractory chronic neuropathic pain. The potential use in outpatient settings warrants further high-quality studies.</p>","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"353-362"},"PeriodicalIF":1.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Oral Ketamine as an Analgesic Therapy: Systematic Review of Randomised Clinical Trials.\",\"authors\":\"María Alejandra Umbacia, Agnès Calsina-Berna, Angie Nathalia Hernández-Rico, Fernan Alejandro Mendoza-Montenegro, Juan Sebastián Gallo-Hincapié, Lina Marcela Ruiz Cadena, María Fernanda Martínez-Díaz, Sebastian Del Castillo Visbal, Juan Esteban Correa-Morales\",\"doi\":\"10.1080/15360288.2025.2496520\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Ketamine is an analgesic used to manage neuropathic pain, but its use is limited by side effects and intravenous administration. Recently, the use of oral and nasal administration has expanded. However, no systematic review of randomized studies on its efficacy and safety. A search was conducted in PubMed, CINHAL, and Web of Science up to December 19, 2023. Randomized studies evaluating oral ketamine for managing any type of pain were included. Articles were assessed for quality using the ROB2 tool, and results were reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The search yielded 1439 results. Six randomized studies were selected. The oral ketamine dose ranged from 0.5 to 10 mg/kg, up to a maximum of 400 mg/day. Three studies comparing oral ketamine with other analgesics found no differences between groups. Two studies compared oral ketamine to placebo; one showed a reduction in local anesthetic use and intraoperative pain, while the other found no difference. Adverse reactions were common, but their severity was not reported. Preliminary evidence suggests that oral ketamine may be considered in select patients with refractory chronic neuropathic pain. The potential use in outpatient settings warrants further high-quality studies.</p>\",\"PeriodicalId\":16645,\"journal\":{\"name\":\"Journal of Pain & Palliative Care Pharmacotherapy\",\"volume\":\" \",\"pages\":\"353-362\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pain & Palliative Care Pharmacotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/15360288.2025.2496520\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/30 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"ANESTHESIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pain & Palliative Care Pharmacotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/15360288.2025.2496520","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
氯胺酮是一种用于治疗神经性疼痛的镇痛药,但其使用受到副作用和静脉注射的限制。最近,口服和鼻腔给药的使用已经扩大。然而,尚无关于其有效性和安全性的随机研究的系统评价。在PubMed, CINHAL和Web of Science中进行了搜索,截止到2023年12月19日。随机研究评估口服氯胺酮管理任何类型的疼痛。使用ROB2工具评估文章的质量,并根据系统评价和荟萃分析指南的首选报告项目报告结果。搜索产生了1439个结果。选择了6个随机研究。口服氯胺酮剂量为0.5至10毫克/公斤,最高可达400毫克/天。三个比较口服氯胺酮和其他镇痛药的研究发现两组之间没有差异。两项研究比较了口服氯胺酮和安慰剂;其中一组显示局部麻醉剂的使用和术中疼痛的减少,而另一组没有发现差异。不良反应很常见,但其严重程度未见报道。初步证据表明,口服氯胺酮可用于难治性慢性神经性疼痛患者。在门诊的潜在应用需要进一步的高质量研究。
Oral Ketamine as an Analgesic Therapy: Systematic Review of Randomised Clinical Trials.
Ketamine is an analgesic used to manage neuropathic pain, but its use is limited by side effects and intravenous administration. Recently, the use of oral and nasal administration has expanded. However, no systematic review of randomized studies on its efficacy and safety. A search was conducted in PubMed, CINHAL, and Web of Science up to December 19, 2023. Randomized studies evaluating oral ketamine for managing any type of pain were included. Articles were assessed for quality using the ROB2 tool, and results were reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The search yielded 1439 results. Six randomized studies were selected. The oral ketamine dose ranged from 0.5 to 10 mg/kg, up to a maximum of 400 mg/day. Three studies comparing oral ketamine with other analgesics found no differences between groups. Two studies compared oral ketamine to placebo; one showed a reduction in local anesthetic use and intraoperative pain, while the other found no difference. Adverse reactions were common, but their severity was not reported. Preliminary evidence suggests that oral ketamine may be considered in select patients with refractory chronic neuropathic pain. The potential use in outpatient settings warrants further high-quality studies.